UNSPSC 51183406: Mitiglinide calcium dihydrate

This classification denotes an anti-diabetic agent 2C19H24NO3.Ca.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9651C21W3Z, chemically known as bis((2s)-2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionate) calcium dihydrate, d-, but more generally known as mitiglinide calcium dihydrate, which bears US NIH Compound Identifier 6918235. European Medicines Agency schedules Mitiglinide calcium dihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21788.

UNSPSC 51183406 Mitiglinide calcium dihydrate is a Commodity code that encompasses prescription pharmaceutical products sold through state and local cooperative purchasing agreements. State and local governments procure under this code primarily through multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and establish master supply agreements with pharmaceutical manufacturers. The purchasing model focuses on generic multi-source pharmaceuticals distributed through authorized wholesale channels, with contracts establishing pricing schedules, product availability timelines, and compliance requirements including current Good Manufacturing Practices certification and Drug Supply Chain Security Act adherence. Issuing bodies include state departments of administration and procurement offices administering cooperative purchasing vehicles that extend eligibility to participating state agencies, county facilities, cities, and other local government entities across multiple states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effective date. The procurement covers participating government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026. Award criteria weighted price competitiveness at 75 percent, fixed pricing at 10 percent, and compliance metrics (EDI capability, administrative fee format, and fee acceptance) at 5 percent each. Vendors must maintain contractual relationships with at least two of the three wholesalers, carry specified insurance coverage including $5 million commercial general liability, and accept a 3 percent administrative fee on all contract purchases, with performance penalties of $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions.